Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1284 participants.
Also called NCT02168829
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 1,284 participants
- Sponsor
- Registry
-
NCT02168829
-
- Other papers using this trial's data
- Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Belgium, Canada, China, Germany, Israel
- Registry status
- Completed
Technical summary
Registry record NCT02168829. Randomized; no masking; primary purpose prevention. Start 2016-01 (actual); primary completion 2025-08-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
- Acronym
- OCEAN
- Condition
- Atrial Fibrillation
- Condition
- Stroke
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Acetylsalicylic acid
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Collaborator
- Canadian Institutes of Health Research (CIHR)
- Collaborator
- Bayer
- Collaborator
- Biotronik Canada Inc
- Collaborator
- Abbott
Record details
- Record id
cardio:ct-nct02168829- Content hash
7d410ba96a40f71c0c537c13c946368f7790033b5036e934d9ff47d0a2e58927